ArticleBMC infectious diseases2026
Prevalence of multidrug resistant and ESBL producing Enterobacteriaceae among patients with urinary tract infections in Southwest Shewa, Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Emergence of Fosfomycin Resistance Among ESBL-ProducingHealth science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUropathogenic Enterobacteriaceae with multidrug resistance (MDR) have become a significant threat to global healthcare systems in the treatment of urinary tract infections (UTIs). This present study aimed to evaluate the prevalence of MDR and Extended-Spectrum Beta-Lactamases (ESBL)-producing Enterobacteriaceae among patients suspected of having UTIs in the Southwest Shewa Zone of Ethiopia.
methodsA hospital-based cross-sectional study was conducted from January to March 2025. Midstream urine specimens were collected from 278 consecutive patients with urinary tract complaints, along with gathering comprehensive sociodemographic data. Enterobacteriaceae were isolated and identified using Gram staining and biochemical characteristics. Antibiotic susceptibility was determined using the Kirby-Bauer method on Mueller-Hinton agar. Logistic regression analysis was employed to identify factors linked to MDR-Enterobacteriaceae-related UTIs, considering a statistically significant P value of < 0.05.
resultAmong the 278 enrolled patients, Enterobacteriaceae were recovered from 16.9% (47/278) of urine samples. Of these, 51.1% (24/47) were multidrug-resistant Enterobacteriaceae (MDRE) and 44.7% (21/47) were extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE). Escherichia coli predominated among MDRE isolates (38.3%, 18/47), while Klebsiella spp. demonstrated the highest species-level MDR rate (62.5%, 5/8). The isolates exhibited high-level resistance to ampicillin (63.8%, 30/47). Notably, all isolates remained susceptible to piperacillin-tazobactam or carbapenems. ESBL production, a history of UTI, and prior antibiotic use were identified as statistically significant factors associated with MDRE-related UTIs. Among these, prior antibiotic use emerged as the most statistically significant independent predictor of MDRE isolation in patients suspected of having UTIs (AOR 9.38, 95% CI: 1.30-67.65; p = 0.026).
conclusionEnterobacteriaceae isolates from UTI-suspected patients in the study area exhibit a significant and escalating incidence of multidrug resistance. Therefore, the treatment of UTI should be informed by antimicrobial susceptibility patterns to ensure the judicious prescription of antibiotics. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.